纽约 - 市值753万美元、上周股价强势上涨25%的生物制药公司Hoth Therapeutics, Inc. (NASDAQ: HOTH)今日宣布,计划为其治疗候选药物HT-001提交扩展使用申请。该药物旨在治疗由抑制表皮生长因子受体 (EGFR)的癌症治疗所引起的皮肤症状。根据 InvestingPro 分析,该公司资产负债表健康,现金储备超过债务。
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They ...
纽约 - 市值718万美元的微型生物科技公司Hoth Therapeutics, Inc. (NASDAQ: HOTH)报告了其治疗候选药物HT-001在治疗癌症相关皮肤毒性方面取得积极临床成果。该公司股票表现强劲,过去一周上涨超过31%。根据 InvestingPro 数据显示,公司现金储备超过债务,维持健康的资产负债表。公司宣布,最近的一项案例研究表明,HT-001 ...
Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...
Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor ...
(PRNewsfoto/Hoth Therapeutics Inc.) "These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment," said Robb Knie CEO of Hoth Therapeutics.
来自MSN2 个月
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy ...Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...
Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing ...
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...
"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果